Skip to main content
. Author manuscript; available in PMC: 2020 Nov 13.
Published in final edited form as: Cell Host Microbe. 2019 Oct 24;26(5):591–600.e4. doi: 10.1016/j.chom.2019.10.001

Figure 2. RhAd52 and Ad26 ZIKV Vaccines Protect Pregnant Mice Against ZIKV Challenge.

Figure 2.

(A) Study schematic design. IFN-αβR−/− mice were vaccinated IM with 109 vp of RhAd52.M-Env (RhAd52), Ad26.M-Env (Ad26), or PBS (Sham). At week 4 after vaccination, IFN-αβR−/− dams were crossed with wildtype males. Pregnant dams were challenged IV with 102 PFU ZIKV-BR on day e5.5 followed by harvest of tissues on day e17.5.

(B) Log ZIKV-specific Env binding antibody titers measured by ELISA in vaccinated versus sham mice at 4 weeks after vaccination.

(C) Log ZIKV-specific microneutralization (MN50) titers in vaccinated versus sham mice at 4 weeks after vaccination.

(D-H) Log ZIKV RNA measured by RT-PCR in maternal serum, spleen, lymph node (LN), ovary, and brain.

Data are representative of independent compiled experiments with 9 to 13 animals per group. Each dot represents an individual mouse. p values were calculated using Mann-Whitney U. Mean ± SEM is shown. The dotted line indicates the limit of detection of the assay.